Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046310 | PMC |
| http://dx.doi.org/10.1111/bjh.15859 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictors of Survival, Treatment Modalities, and Clinical Outcomes of Diffuse Large B-Cell Lymphoma in Patients Older Than 70 Years Still an Unmet Medical Need in 2024 Based on Real-World Evidence.
Cancers (Basel)
April 2024
Department of Hematology, Hemotherapy & Cell Therapy, Faculty of Medicine, University of São Paulo (FM-USP), São Paulo 05403000, Brazil.
Background: Diffuse large B-cell lymphoma (DLBCL) especially affects the older population. Old (≥60 years) and very old age (≥80 years) DLBCL patients often present high-risk molecular alterations, lower tolerability to conventional immunochemotherapy, and poor clinical outcomes. In this scenario, attenuated therapeutic strategies, such as the R-MiniCHOP and R-MiniCHOP of the elderly regimens, have emerged for this particularly fragile population.
View Article and Find Full Text PDF[The Value of Baseline PET/CT Imaging of Bone Marrow F-FDG Uptake Pattern in Predicting Prognosis of DLBCL].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
April 2024
Department of Medical Imaging, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Objective: To investigate the prognostic value of bone marrow uptake pattern in F-deoxyglucose (F-FDG) PET/CT imaging before diffuse large B-cell lymphoma (DLBCL) treatment.
Methods: The clinical data of 156 patients with DLBCL were retrospectively analyzed. All patients underwent bone marrow biopsy, bone marrow smear, flow cytometry and F-FDG PET/CT scan before treatment.
Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models.
Blood Cancer J
October 2023
Department of Hematology, Odense University Hospital, Odense, Denmark.
Currently, the International Prognostic Index (IPI) is the most used and reported model for prognostication in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). IPI-like variations have been proposed, but only a few have been validated in different populations (e.g.
View Article and Find Full Text PDFExternal validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival.
Hematology
December 2022
Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. The standard first-line therapy for DLBCL consists of rituximab cyclophosphamide doxorubicin vincristine and prednisone (R-CHOP). About 50-70% of patients may be cured by R-CHOP.
View Article and Find Full Text PDFA Comparison of Clinical Prognostic Indices in Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with a Pegylated Liposomal Doxorubicin Combination Regimen in China.
Cancer Manag Res
September 2022
Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
Background: There is no consensus regarding the risk stratification scores for elderly patients with diffuse large B-cell lymphoma (DLBCL). We aimed to compare the prognostic predictive ability of the current clinical scoring indices in DLBCL elderly patients treated with the R-CODP regimen (rituximab, cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone).
Methods: We retrospectively collected the data of elderly DLBCL patients who received the R-CODP regimen as the first-line treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!